News - Lyrica

Filter

Current filters:

Lyrica

Popular Filters

Mixed results for Pfizer’s two Lyrica Phase IIIb studies

Mixed results for Pfizer’s two Lyrica Phase IIIb studies

21-10-2013

Pfizer has announced mixed results from two Phase IIIb studies of Lyrica capsules CV in patients with…

AnalgesiaLyricaNorth AmericaPfizerPharmaceuticalResearch

Pfizer's Lyrica equals levetiracetam in patients with partial onset seizures

22-02-2013

Global pharma behemoth Pfizer (NYSE: PFE) has announced top-line results from a Phase III study showing…

LyricaNeurologicalPfizerPharmaceuticalResearch

Pfizer's Lyrica misses primary endpoint in seizure frequency trial; positive in fibromyalgia

20-11-2012

US pharma behemoth Pfizer (NYSE: PFE) revealed disappointing top-line results of a double-blind, placebo-controlled,…

LyricaNeurologicalPfizerPharmaceuticalResearch

Australia to add Pfizer's Lyrica to PBS list; call for antibiotic research incentives

18-11-2012

Australia's Health Minister Tanya Plibersek on Friday announced the government's decision to subsidize…

Asia-PacificLyricaPfizerPharmaceuticalPricingRegulationResearch

Pfizer's Lyrica positive in two post-marketing studies

23-07-2012

Top-line results for global drugs behemoth Pfizer's already marketed diabetic nerve pain and post-herpetic…

LyricaNeurologicalPfizerPharmaceuticalReproductiveResearch

US Court confirms Pfizer patents on Lyrica valid through 2018

23-07-2012

The US District Court for the District of Delaware upheld the Pfizer (NYSE: PFE) composition of matter…

GenericsLegalLyricaNeurologicalNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical Industries

Lilly/Boehringer Ingelheim's Cymbalta now fibromyalgia market leader in USA

22-07-2012

US drug major Eli Lilly (NYSE: LLY) and German independent Boehringer Ingelheim's Cymbalta (duloxetine)…

Boehringer IngelheimCymbaltaEli LillyGlobalLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceutical

US FDA approves generics for Actavis and Lupin

06-07-2012

Switzerland-based generic drugmaker Actavis Group, now owned by US firm Watson Pharmaceuticals (NYSE:…

ActavisGenericsIntunivLupinLyricaNeurologicalNorth AmericaPfizerRegulationShireWatson Pharmaceuticals

Pfizer's Lyrica cleared for spinal cord injury pain in USA

22-06-2012

The US Food and Drug Administration has approved the use of Lyrica (pregabalin) capsules CV for the management…

LyricaNeurologicalNorth AmericaPfizerPharmaceuticalRegulation

Pfizer reports disappointment with Ph III trials of Lyrica in extended indications

08-05-2012

US drugs behemoth Pfizer (NYSE; PFE) had a setback with extending the use of its blockbuster drug Lyrica…

LyricaNeurologicalPfizerPharmaceuticalResearch

Global pain management drugs market to see moderate growth as generic share continues to rise

24-11-2011

In 2010, the global pain management market was worth approximately $28.6 billion, representing a compound…

CelebrexCymbaltaEli LillyGlobalLyricaMarkets & MarketingNeurologicalPfizerPharmaceutical

Pfizer out-licenses neratinib to Puma Biotech; stops Lyrica epilepsy trial on good efficacy

07-10-2011

In a second drug candidate sale this week, pharma behemoth Pfizer (NYSE: PFE) has agreed to sell rights…

FinancialLicensingLyricaNeurologicalOncologyPfizerPharmaceuticalPuma BiotechResearch

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top